Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Human telomerase reverse transcriptase (hTERT) is a target antigen for cancer immunotherapy in patients with non-small cell lung cancer (NSCLC). We have tested a novel hTERT vaccine, UV1, designed to give high population coverage. UV1 is composed of three synthetic long peptides containing multiple...
Main Authors: | Paal F. Brunsvig, Tormod Kyrre Guren, Marta Nyakas, Claudius H. Steinfeldt-Reisse, Wenche Rasch, Jon Amund Kyte, Hedvig Vidarsdotter Juul, Steinar Aamdal, Gustav Gaudernack, Else Marit Inderberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.572172/full |
Similar Items
-
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
by: Sara M Mangsbo, et al.
Published: (2022-05-01) -
Mechanisms of nucleotide selection by telomerase
by: Matthew A Schaich, et al.
Published: (2020-06-01) -
382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma
by: Sara Mangsbo, et al.
Published: (2021-11-01) -
Telomerase: An exploration toward the end of cancer
by: Deepika Bablani Popli, et al.
Published: (2017-01-01) -
The Processivity of Telomerase: Insights from Kinetic Simulations and Analyses
by: Clive R. Bagshaw, et al.
Published: (2021-12-01)